F W P J van den Berkmortel
Overview
Explore the profile of F W P J van den Berkmortel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
75
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lammers S, Geurts S, Hermans K, Kooreman L, Swinkels A, Smorenburg C, et al.
ESMO Open
. 2025 Feb;
10(2):104154.
PMID: 39921934
Background: This study determines the prognostic value of the luminal-like subtype in patients with hormone receptor-positive breast cancer and explores whether the efficacy of extended anastrozole therapy differs between patients...
2.
Ozkan A, Kapiteijn E, van den Bos F, Aarts M, van den Berkmortel F, Blank C, et al.
Eur J Cancer
. 2024 Dec;
216:115194.
PMID: 39732138
No abstract available.
3.
Ozkan A, Kapiteijn E, van den Bos F, Aarts M, van den Berkmortel F, Blank C, et al.
Eur J Cancer
. 2024 Oct;
212:115056.
PMID: 39368226
Background: Adjuvant anti-PD-1 therapy improves relapse free survival in stage III melanoma, but also leads to immune-related adverse events (irAEs). Older patients are of particular interest due to comorbidities and...
4.
van Duin I, Schuiveling M, Ter Maat L, Veta M, van Eijs M, Verheijden R, et al.
Immunooncol Technol
. 2024 Jul;
24:100714.
PMID: 39045171
Background: The predictive value of tumor-infiltrating lymphocytes (TILs) in immune-related adverse event (irAE) development remains unknown, although an association between tumor immunogenicity and irAEs has been suggested. We investigated the...
5.
Janssen J, van Dijk B, de Joode K, Aarts M, van den Berkmortel F, Blank C, et al.
BMC Cancer
. 2024 May;
24(1):632.
PMID: 38783238
Background: Patients with irresectable stage III or metastatic melanoma presenting with poor prognostic factors are usually treated with a combination of immune checkpoint inhibitors (ICIs), consisting of ipilimumab and nivolumab....
6.
Borgers J, Burgers F, Schina A, Van Not O, van den Eertwegh A, Blank C, et al.
Pigment Cell Melanoma Res
. 2023 Aug;
37(1):15-20.
PMID: 37554041
Despite the improved survival rates of patients with advanced stage melanoma since the introduction of ICIs, many patients do not have (long-term) benefit from these treatments. There is evidence that...
7.
Creemers S, Van Santvoort B, van den Berkmortel F, Kiemeney L, van Oort I, Aben K, et al.
Prostate Cancer Prostatic Dis
. 2022 Jul;
26(1):133-141.
PMID: 35798856
Background: The recommended treatment for a subset of patients with metastatic prostate cancer (mPC) changed from androgen deprivation therapy (ADT) to combinations with chemotherapy such as docetaxel. Implementation of new...
8.
Franken M, Leeneman B, Aarts M, van Akkooi A, van den Berkmortel F, Boers-Sonderen M, et al.
ESMO Open
. 2021 Dec;
6(6):100320.
PMID: 34856511
Background: The objective of this study was to evaluate trends in survival and health care costs in metastatic melanoma in the era of targeted and immunotherapeutic drugs. Materials And Methods:...
9.
Suijkerbuijk K, Haanen J, Boers-Sonderen M, Hospers G, Blank C, van den Berkmortel F, et al.
J Eur Acad Dermatol Venereol
. 2021 Sep;
36(2):e118-e119.
PMID: 34536304
No abstract available.
10.
Beukers K, Bessems S, van de Wouw A, van den Berkmortel F, Belgers H, Konsten J, et al.
J Geriatr Oncol
. 2021 May;
12(8):1166-1172.
PMID: 34006492
Objectives: Feasible screening methods are important to identify older patients who might benefit from adjuvant chemotherapy. The aim of this study was to investigate the associations between the outcomes of...